Biopharmaceutical Company NuPathe Inc. (PATH) said Tuesday that the company's New Drug Application, or NDA, resubmission for its migraine patch, NP101, was accepted for filing by the U.S. Food and Drug Administration. NuPathe also said it obtained a Prescription Drug User Fee Act, or PDUFA, date, of January 17, 2013, to complete its review of the NDA. Armando Anido, chief executive officer of NuPathe, said in a statement, "We look forward to working closely with the FDA to complete its review and to bringing our innovative new treatment option to migraine patients in 2013."
Migraine Patch, NP101, is an active, single-use, transdermal patch in development for the treatment of migraine. If approved, it will be the first transdermal patch for the treatment of migraine.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.